Calendar

Carnival's demand and booking backdrop is excellent, but this is exactly the kind of setup where strong business momentum may already be understood: Zacks showed a negative ESP and management's Q2 adjusted EPS guide sat below consensus because fuel costs were overwhelming otherwise strong demand.

Fervo has an attractive secular story, but the checked pre-event sources mainly confirmed the date and did not deliver a credible paired upcoming EPS and revenue consensus set, so it fails the screen's reliability requirement.

Sunbelt's underlying rental business looked fundamentally okay, but accessible pre-event sources did not provide a credible paired consensus EPS and consensus revenue package, so it cannot qualify under the screen rules despite a confirmed earnings date and acceptable operating backdrop.

Korn Ferry was rejected because the checked third-party source showed it had already reported on June 17, 2026, conflicting with the supplied universe date of June 23, 2026; once the event is already past, the pre-event setup cannot be reliably underwritten inside this window.

FedEx has a plausible upside-surprise setup because the company already posted a strong prior quarter, raised FY26 outlook, and previews call for nearly 9% revenue growth while the stock has outperformed transportation peers; the setup stays speculative because accessible volume was below average and the close-location signal was only middling.

Cerebras may have strong narrative momentum, but accessible pre-event sources did not provide a credible paired consensus EPS and revenue package, and public financial data availability was poor, so the name cannot clear the screen's minimum reliability bar.

General Mills lacked the surprise-screen ingredients: accessible sources showed a prior miss, soft category growth expectations, and even an earnings-date mismatch check versus the supplied universe, making the setup too noisy to underwrite as a positive pre-print surprise.

KB Home did not fit the upside-surprise template because accessible previews pointed to sharply lower revenue, unchanged consensus, and no verified positive tape or volume signal.

Paychex has a stable business and prior beat history, but the stock's accessible tape was weak-to-mixed and no strong fresh revision or volume signal was verified ahead of earnings.

McCormick's setup looked steady rather than asymmetric: modest growth, no clearly positive revision signal, and no verified volume or close-location confirmation kept it well below the screen threshold.

NOVAGOLD is not suitable for this screen because checked public materials did not provide a credible current-quarter revenue consensus and the company remains a project-development story rather than a normal operating earnings setup. That makes surprise probability hard to measure using the rules required here.

Micron has the cleanest pre-print fundamental setup in the window: Zacks flagged a positive ESP, revenue expectations are still rising into a company-described record quarter, and management is explicitly tying demand to HBM and AI memory strength; the only notable blemish is that recent equity volume looks elevated but not clearly above the 1.5x hurdle.

Nike remained a turnaround story rather than a clean upside-surprise setup: accessible previews showed modest EPS expectations, recent stock and sector checks were not decisively strong, and no positive revision or strong tape/volume confirmation was verified.

Jefferies has a decent revenue-growth setup into earnings, but the checked preview set did not show a clean positive ESP/revision signal and accessible tape confirmation was too thin to elevate it above a near miss.

H.B. Fuller showed some earnings resilience, but accessible sources did not verify a strong revenue-upside or tape/volume signal, leaving it below threshold.

Darden has a decent beat-setup signal and solid operating momentum from Q3 same-store sales, but the accessible tape package was too thin to verify a strong close-location or volume-accumulation confirmation, so it stays a near miss rather than a qualified pre-earnings long.

TD SYNNEX looks like a classic estimate-and-tape near miss: estimate revisions moved higher, management posted record Q1 results with constructive Q2 guidance, and the stock has materially outperformed the tech sector into earnings, but accessible tape checks did not show the desired volume surge and the public preview set is thinner than Micron's.

Acuity has respectable operating momentum, especially in AIS, but the accessible pre-event package did not show a strong fresh revision/ESP signal or tape confirmation, so it remains a watch item rather than a qualified surprise setup.

Commercial Metals has improving earnings-growth optics and a clean balance-sheet profile, but the accessible pre-print evidence set lacked a strong revision/ESP confirmation and offered weak tape visibility, leaving it just below the speculative threshold.

The post-earnings tape is only mildly supportive: the capture-time quote was 54.03, down $1.31 (-2.4%) versus the prior close, so investors are not yet paying up for the guidance raise. Analyst revision data was not present in the packet, and coverage remains thin, so conviction stays moderate rather than high. Social context was absent, so this is primarily a primary-source earnings follow-up rather than a crowd-sentiment read.

The primary company source confirms a strong Q4 print and above-Q4 Q1 revenue guide, but secondary headlines show the market reaction was not one-way: Barron's described the stock sinking despite 157% revenue growth, Stocktwits noted an after-hours drop, and later GuruFocus coverage framed the stock as rising on AI expectations. That mix suggests expectations and valuation are the key post-print debate. The packet does not include a complete trusted post-earnings analyst-revision set, and social context is unavailable, so this remains a cautious monitoring-style positive tilt rather than a high-conviction upgrade.

This T+3 follow-up does not show a clean new earnings print or transcript; the actionable company-source evidence is the delayed filing/restatement path, Nasdaq deficiency notice, preliminary 2025 results and 2026 outlook, and executive changes. The market reaction remains headline-sensitive rather than earnings-driven, with HUBG around $43 and down about 1.9% on June 4. Analyst reaction available from trusted market sources is cautious rather than uniformly negative, but missing full financials and delayed filings keep the report tentative.

Primary evidence is strong and company-led: the June 1 8-K/IR release shows a clear beat/raise, and recent news flow shows AI infrastructure enthusiasm around HPE and adjacent hardware names. Post-print analyst reaction appears positive, but the available packet does not provide a complete refreshed consensus or estimate-revision set. I did not rely on social, options, short-interest, or employee-review data here; those fields are left neutral or unavailable. The main caveat is that the initial rerating is already substantial, so this is a follow-through monitoring setup rather than a fresh undiscovered long.

This is a constructive but still cautious T+3 earnings follow-up. Company-source evidence confirms the margin-led beat-and-raise, and checked post-print market coverage reported the shares rose roughly 14% after results to about $114.85. Analyst reaction is available but not broad in the packet: Stifel raised its target to $137 from $120 and kept a Buy rating, while the packet's median target remains near the current price. With no usable social packet and only limited revision detail, the setup improves from the prior monitoring view but does not justify a stronger rating without further bookings and organic-growth confirmation.

This is a T+3 post-earnings follow-up, and the tone stays cautious. The May 7 interim LEGEND update supports ongoing clinical activity and a long cash runway, but it also underscored the durability debate, which is why coverage after the print turned more skeptical. The packet does not provide usable social, options, or employee-data signals, so the report should stay anchored to primary-company sources and the limited secondary reaction already surfaced. The current anchor price of $1.67 still implies that the market is treating the story as a high-risk, event-driven biotech rather than a confirmed rerating candidate.